Related Experiment Video
Updated: Mar 31, 2026
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
8.5K
Nanotherapeutic Interventions for Parkinson's Disease: Modulating Pathogenic Mechanisms and Overcoming Therapeutic
Xuanying Yin1, Chen Wang1, Weisen Lin1
1Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, 510405, People's Republic of China.
International Journal of Nanomedicine
|March 30, 2026
Summary
Nanotechnology offers promising new treatments for Parkinson's disease (PD) by enabling targeted drug delivery to lesions. While a cure is distant, nanomedicines show potential for more effective Parkinson's disease therapies.
Area of Science:
- Neurodegenerative Disorders
- Nanotechnology in Medicine
- Pharmacology
Background:
- Parkinson's disease (PD) is a widespread neurodegenerative disorder with limited effective treatments.
- Complex pathogenesis and lesion specificity hinder current therapeutic approaches for PD.
- Nanotechnology presents novel strategies for advanced Parkinson's disease therapy.
Purpose of the Study:
- To review the pathophysiological mechanisms of Parkinson's disease.
- To provide an overview of nanomedicine-based strategies for targeting PD lesions.
- To summarize clinical trials and the translational potential of nanomedicines for PD.
Main Methods:
- Literature review of Parkinson's disease pathophysiology.
- Analysis of nanomedicine and nanomaterial applications in PD.
- Summary of clinical trials and future prospects for PD nanotherapies.
Main Results:
- Nanomedicines enable precise, targeted drug delivery for PD.
- Nanomaterials can modulate key pathogenic mechanisms in Parkinson's disease.
- Emerging nanotherapies show considerable promise despite being in early stages.
Conclusions:
- Nanomedicine holds transformative potential for developing more effective, targeted Parkinson's disease treatments.
- Continued development of nanotherapies is crucial for advancing PD treatment.
- While a definitive cure is not yet available, nanotechnology offers significant hope for future PD management.
More Related Videos
05:38Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
Published on: January 7, 2019
19.2K
07:14A Novel Approach to Assess Motor Outcome of Deep Brain Stimulation Effects in the Hemiparkinsonian Rat: Staircase and Cylinder Test
Published on: May 31, 2016
15.5K
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:15Parkinson's Disease: Overview
2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
01:22Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
01:28Drug Therapy
401
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
401
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
2.0K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
2.0K
01:27Peripheral Artery Disease III: Interprofessional Care
559
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
559